Great Point Partners LLC
- SEC CIK
- 0001281446
- Latest filing
- Aug 14, 2026
Holdings in Q4 2022
Holdings as of Dec 31, 2022, filed Feb 14, 2023. Long positions only; changes compare share counts with Q3 2022.
- Positions
- 40
- 0 vs. Q3 2022
- Portfolio value
- $483.7M
- +$68.4M (+16.5%) vs. Q3 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| ANABAnaptysbio, Inc | COM | 15,000 | $464.9K | 0.1% | +15,000 | New | History |
| IMUXImmunic, Inc. | COM | 632,184 | $885.1K | 0.2% | +632,184 | New | History |
| ALKSAlkermes plc. | SHS | 46,185 | $1.21M | 0.2% | −461,315−90.9% | Reduced | History |
| EOLSEvolus, Inc. | COM | 190,329 | $1.43M | 0.3% | +190,329 | New | History |
| GBIOGeneration Bio Co. | COM | 1,022,537 | $4.02M | 0.8% | +197,460+23.9% | Added | History |
| Gracell Biotechnologies Inc38406L103 | SPONSORED ADS | 1,962,399 | $4.51M | 0.9% | +1,513,350+337.0% | Added | – |
| DTILPrecision Biosciences Inc | COM | 3,801,305 | $4.52M | 0.9% | +1,090,500+40.2% | Added | History |
| URGNUroGen Pharma Ltd. | COM | 560,000 | $4.97M | 1.0% | −313,424−35.9% | Reduced | History |
| LRMRLarimar Therapeutics, Inc. | COM | 1,273,635 | $5.26M | 1.1% | +138,635+12.2% | Added | History |
| ALBOAlbireo Pharma, Inc. | COM | 267,283 | $5.78M | 1.2% | +267,283 | New | History |
| VERVVerve Therapeutics, Inc. | COM | 300,000 | $5.80M | 1.2% | +300,000 | New | History |
| MRTXMirati Therapeutics, Inc. | COM | 133,000 | $6.03M | 1.2% | +133,000 | New | History |
| ABOSAcumen Pharmaceuticals, Inc. | COM | 1,116,581 | $6.03M | 1.2% | −83,419−7.0% | Reduced | History |
| ICPTIntercept Pharmaceuticals, Inc. | COM | 528,850 | $6.54M | 1.4% | +423,850+403.7% | Added | History |
| ERASErasca, Inc. | COM | 1,538,461 | $6.63M | 1.4% | +1,538,461 | New | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 642,566 | $6.75M | 1.4% | +150,566+30.6% | Added | History |
| AMLXAmylyx Pharmaceuticals, Inc. | COM | 190,000 | $7.02M | 1.5% | +190,000 | New | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 1,055,801 | $7.14M | 1.5% | −495,918−32.0% | Reduced | History |
| SRPTSarepta Therapeutics, Inc. | COM | 73,000 | $9.46M | 2.0% | +73,000 | New | History |
| CBAYCymaBay Therapeutics, Inc. | COM | 1,550,000 | $9.72M | 2.0% | +750,561+93.9% | Added | History |
| TVTXTravere Therapeutics, Inc. | COM | 475,000 | $9.99M | 2.1% | −491,108−50.8% | Reduced | History |
| JBIOJade Biosciences, Inc. | COM | 378,522 | $11.1M | 2.3% | +378,522 | New | History |
| PTCTPTC Therapeutics, Inc. | COM | 302,135 | $11.5M | 2.4% | +302,135 | New | History |
| DAWNDay One Biopharmaceuticals, Inc. | Stock | 544,451 | $11.7M | 2.4% | +473,830+670.9% | Added | History |
| VKTXViking Therapeutics, Inc. | COM | 1,295,034 | $12.2M | 2.5% | +1,295,034 | New | History |
| CINCCinCor Pharma, Inc. | COM | 1,019,153 | $12.5M | 2.6% | +717,829+238.2% | Added | History |
| VTYXVentyx Biosciences, Inc. | COM | 400,695 | $13.1M | 2.7% | +130,728+48.4% | Added | History |
| OPTNOptiNose, Inc. | COM | 7,894,736 | $14.6M | 3.0% | +7,894,736 | New | History |
| RAREUltragenyx Pharmaceutical Inc. | COM | 342,300 | $15.9M | 3.3% | +342,300 | New | History |
| HRTXHeron Therapeutics, Inc. | COM | 6,360,161 | $15.9M | 3.3% | +715,000+12.7% | Added | History |
| ACRSAclaris Therapeutics, Inc. | COM | 1,019,282 | $16.1M | 3.3% | 00.0% | Unchanged | History |
| ISEEIVERIC bio, Inc. | COM | 825,000 | $17.7M | 3.7% | +825,000 | New | History |
| PNTPOINT Biopharma Global Inc. | COM | 2,541,779 | $18.5M | 3.8% | −1,019,205−28.6% | Reduced | History |
| SGENSeagen Inc. | COM | 160,500 | $20.6M | 4.3% | +84,000+109.8% | Added | History |
| JAZZJazz Pharmaceuticals plc | SHS USD | 160,000 | $25.5M | 5.3% | −55,000−25.6% | Reduced | History |
| PLRXPliant Therapeutics, Inc. | COM | 1,322,870 | $25.6M | 5.3% | +281,133+27.0% | Added | History |
| ALPNAlpine Immune Sciences, Inc. | COM | 3,637,718 | $26.7M | 5.5% | +189,197+5.5% | Added | History |
| RAPTRAPT Therapeutics, Inc. | COM | 1,436,569 | $28.4M | 5.9% | +1,121,569+356.1% | Added | History |
| XENEXenon Pharmaceuticals Inc. | COM | 850,000 | $33.5M | 6.9% | 00.0% | Unchanged | History |
| PCVXVaxcyte, Inc. | COM | 800,000 | $38.4M | 7.9% | +200,000+33.3% | Added | History |
Options (2)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
Sold out since Q3 2022 (15)
Positions held at the end of Q3 2022 that are gone from this filing.
| Security | Class | Shares in Q3 2022 | Value in Q3 2022 | % of portfolio in Q3 2022 | History |
|---|---|---|---|---|---|
| RLMDRelmada Therapeutics, Inc. | COM | 510,000 | $18.9M | 4.5% | History |
| LKFTLakefront Biotherapeutics NV | SPON ADR | 306,411 | $13.1M | 3.1% | History |
| BBIOBridgeBio Pharma, Inc. | COM | 1,050,000 | $10.4M | 2.5% | History |
| TCDATricida, Inc. | COM | 870,000 | $9.12M | 2.2% | History |
| REPLReplimune Group, Inc. | COM | 390,000 | $6.74M | 1.6% | History |
| MDGLMadrigal Pharmaceuticals, Inc. | COM | 95,500 | $6.21M | 1.5% | History |
| MISTMilestone Pharmaceuticals Inc. | COM | 674,656 | $6.20M | 1.5% | History |
| ETNB89bio, Inc. | COM | 955,000 | $5.53M | 1.3% | History |
| NGMNGM Biopharmaceuticals Inc | COM | 316,256 | $4.14M | 1.0% | History |
| IMCRImmunocore Holdings plc | ADS | 78,527 | $3.69M | 0.9% | History |
| Pieris Pharmaceuticals Inc720795103 | COM | 1,965,449 | $2.26M | 0.5% | – |
| DNTHDianthus Therapeutics, Inc. | COM | 1,019,091 | $1.44M | 0.3% | History |
| NKTRNektar Therapeutics | COM | 447,820 | $1.43M | 0.3% | History |
| SYRESpyre Therapeutics, Inc. | COM | 2,500,000 | $1.31M | 0.3% | History |
| SLNSilence Therapeutics plc | ADS | 68,915 | $692.0K | 0.2% | History |